Blocking GluR2–GAPDH ameliorates experimental autoimmune encephalomyelitis

Annals of Clinical and Translational Neurology

Volumn 2, Issue 4, 2015, Pages 388-400

  Zhai, Dongxu ^a   Lee, Frankie H F ^a   D’Souza, Cheryl ^b   Su, Ping ^a   Zhang, Shouping ^c   Jia, Zhengping ^c   Zhang, Li ^b,d   Wong, Albert H C ^a,e   Liu, Fang ^a,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84962715710     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/ACN3.182     Document Type: Article

References (28)

1. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2015;2:388–400.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502–1517.
3. Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 2007;20:286–293.
4. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247–269.
5. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012;13:507–514.
6. Bolton C, Paul C. Glutamate receptors in neuroinflammatory demyelinating disease. Mediators Inflamm 2006;2006:93684.
7. Newcombe J, Uddin A, Dove R, et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 2008;18:52–61.
8. Basso AS, Frenkel D, Quintana FJ, et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Investig 2008;118:1532–1543.
9. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62–66.
10. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67–70.
11. Villoslada P, Arrondo G, Sepulcre J, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009;72:1630–1633.
12. Wang M, Li S, Zhang H, et al. Direct interaction between GluR2 and GAPDH regulates AMPAR-mediated excitotoxicity. Mol Brain 2012;5:13.
13. Zhai D, Li S, Wang M, et al. Disruption of the GluR2/ GAPDH complex protects against ischemia-induced neuronal damage. Neurobiol Dis 2013;54:392–403.
14. Soulika AM, Lee E, McCauley E, et al. Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci 2009;29:14965–14979.
15. Bannerman P, Hahn A, Ramirez S, et al. Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice. Brain 2005;128:1877–1886.
16. Liu L, Huang D, Matsui M, et al. Severe disease, unaltered leukocyte migration, and reduced IFN-c production in CXCR3 / mice with experimental autoimmune encephalomyelitis. J Immunol 2006;176:4399–4409.
17. Lubetzki C, Williams A, Stankoff B. Promoting repair in multiple sclerosis: problems and prospects. Curr Opin Neurol 2005;18:237–244.
18. Rivers TM, Schwentker FF. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 1935;61:689–702.
19. Miller SD, Karpus WJ, Davidson TS. Experimental autoimmune encephalomyelitis in the mouse. Current protocols in immunology 2007: 15.1. 1–.1. 20
20. Lyons JA, San M, Happ MP, Cross AH. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999;29:3432–3439.
21. Zhai D, Chin K, Wang M, Liu F. Disruption of the nuclear p53-GAPDH complex protects against ischemiainduced neuronal damage. Mol Brain 2014;7:20.
22. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123(Pt 6):1174–1183.
23. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014;89:225–240.
24. Ontaneda D, Hyland M, Cohen JA. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu Rev Med 2012;63:389–404.
25. Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984;226: 850–852.
26. Roesler R, Quevedo J, Schroder N. Is it time to conclude that NMDA antagonists have failed? Lancet Neurol 2003;2:13; discussion.
27. Meng Y, Zhang Y, Jia Z. Synaptic transmission and plasticity in the absence of AMPA glutamate receptor GluR2 and GluR3. Neuron 2003;39:163–176.
28. Kanwar JR, Kanwar RK, Krissansen GW. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 2004;127(Pt 6):1313–1331.